This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 2007 May 1;109(9):4106-7.

doi: 10.1182/blood-2006-12-061135.

Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation

Kais Hussein, Oliver Bock, Anna Seegers, Michael Flasshove, Felicitas Henneke, Guntram Buesche, Hans Heinrich Kreipe

PMID: 17449802
DOI: 10.1182/blood-2006-12-061135

Free article

Case Reports

Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation

Kais Hussein et al. Blood. 2007.

Free article

. 2007 May 1;109(9):4106-7.

doi: 10.1182/blood-2006-12-061135.

Authors

Kais Hussein, Oliver Bock, Anna Seegers, Michael Flasshove, Felicitas Henneke, Guntram Buesche, Hans Heinrich Kreipe

PMID: 17449802
DOI: 10.1182/blood-2006-12-061135

No abstract available

PubMed Disclaimer

Similar articles

Disappearance of both the BCR/ABL1 fusion gene and the JAK2V617F mutation with dasatinib therapy in a patient with imatinib-resistant chronic myelogenous leukemia.
Inokuchi K, Yamaguchi H, Tamai H, Dan K. Inokuchi K, et al. J Clin Exp Hematop. 2012;52(2):145-7. doi: 10.3960/jslrt.52.145. J Clin Exp Hematop. 2012. PMID: 23037633 No abstract available.
Effects of Jak2 type 1 inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 mutation-positive and Bcr-Abl-positive cell lines.
Ringel F, Kaeda J, Schwarz M, Oberender C, Grille P, Dörken B, Marque F, Manley PW, Radimerski T, le Coutre P. Ringel F, et al. Acta Haematol. 2014;132(1):75-86. doi: 10.1159/000356784. Epub 2014 Jan 31. Acta Haematol. 2014. PMID: 24504330
[Chronic myeloid leukemia: up-to-date management].
Nakayama K, Inokuchi K. Nakayama K, et al. Rinsho Ketsueki. 2014 Jan;55(1):42-55. Rinsho Ketsueki. 2014. PMID: 24492036 Review. Japanese. No abstract available.
[Clinical progress in chronic myelogenous leukemia].
Matsunaga T. Matsunaga T. Rinsho Ketsueki. 2009 Oct;50(10):1489-99. Rinsho Ketsueki. 2009. PMID: 19915358 Review. Japanese. No abstract available.
Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, Gardembas M, Etienne G, Réa D, Roy L, Escoffre-Barbe M, Guerci-Bresler A, Tulliez M, Prost S, Spentchian M, Cayuela JM, Reiffers J, Chomel JC, Turhan A, Guilhot J, Guilhot F, Mahon FX. Rousselot P, et al. J Clin Oncol. 2014 Feb 10;32(5):424-30. doi: 10.1200/JCO.2012.48.5797. Epub 2013 Dec 9. J Clin Oncol. 2014. PMID: 24323036

See all similar articles

Cited by

Successful Treatment of a Patient with Chronic Myelogenous Leukemia with Concurrent Janus Kinase 2 (JAK2) R795S Mutation and Breakpoint Cluster Region-ABL1 (BCR-ABL1) Fusion: A Case Report and Literature Review.
Yue Y, Wei W, Guo Y, Wang F, Dong W, Liu Y, Lin Y, Cao Y, Gu W. Yue Y, et al. Am J Case Rep. 2020 Oct 6;21:e925151. doi: 10.12659/AJCR.925151. Am J Case Rep. 2020. PMID: 33021971 Free PMC article. Review.
A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders.
Bee PC, Gan GG, Nadarajan VS, Latiff NA, Menaka N. Bee PC, et al. Int J Hematol. 2010 Jan;91(1):136-9. doi: 10.1007/s12185-009-0471-6. Epub 2010 Jan 5. Int J Hematol. 2010. PMID: 20047097
Cytokine-induced killer cells: new insights for therapy of hematologic malignancies.
Ghanbari Sevari F, Mehdizadeh A, Abbasi K, Hejazian SS, Raeisi M. Ghanbari Sevari F, et al. Stem Cell Res Ther. 2024 Aug 13;15(1):254. doi: 10.1186/s13287-024-03869-z. Stem Cell Res Ther. 2024. PMID: 39135188 Free PMC article. Review.
ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia.
Schönfeld L, Rinke J, Hinze A, Nagel SN, Schäfer V, Schenk T, Fabisch C, Brümmendorf TH, Burchert A, le Coutre P, Krause SW, Saussele S, Safizadeh F, Pfirrmann M, Hochhaus A, Ernst T. Schönfeld L, et al. Leukemia. 2022 Sep;36(9):2242-2249. doi: 10.1038/s41375-022-01648-4. Epub 2022 Jul 28. Leukemia. 2022. PMID: 35902731 Free PMC article.
Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm.
Hassan A, Dogara LG, Babadoko AA, Awwalu S, Mamman AI. Hassan A, et al. Niger Med J. 2015 Jan-Feb;56(1):74-6. doi: 10.4103/0300-1652.149177. Niger Med J. 2015. PMID: 25657500 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Silverchair Information Systems
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal